Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Cleveland Life Science Advisors (CLSA) is a venture capital firm based in Cleveland, Ohio, dedicated to early-stage investments in the life sciences sector. Founded to capitalize on the potential of Cleveland and the Greater Midwest, CLSA aims to invest in technologies that can significantly impact patient care. The firm operates the Cleveland Life Sciences Accelerator Fund, which has a fund size of approximately $2.7 million, backed by around 24 individual investors.
CLSA's investment strategy encompasses pre-seed, seed, seed-plus, and Series A stages, focusing on biotech, medtech, and healthcare companies. The organization emphasizes strong intellectual property and exceptional market opportunities, targeting innovations that promise both financial returns and humanitarian impact. Their portfolio currently includes 10 companies, showcasing their commitment to fostering innovation in the life sciences.
Notable milestones for CLSA include partnerships with academic institutions like Case Western Reserve University, which enhance their ability to support portfolio companies. The firm is strategically positioned to leverage the resources and talent available in Northeast Ohio, aiming to drive meaningful advancements in patient care through its investments.
CLSA invests in early-stage companies within the life sciences sector, particularly those that demonstrate exceptional market opportunities and strong intellectual property. Their investment strategy includes a combination of strategic buyouts and initial public offerings (IPOs), typically within a 3-5 year timeframe. The firm is particularly interested in innovations that can deliver both financial returns and humanitarian impact.
Target sectors include biotech and healthcare, with a keen focus on technologies that can lead to transformative healthcare solutions. CLSA seeks companies that not only have strong intellectual property but also the potential to significantly improve patient care. The organization emphasizes the importance of market potential and aims to partner with founders who share a vision for impactful healthcare advancements.
CLSA's portfolio includes a diverse range of companies that are making significant strides in the life sciences sector. Notable portfolio companies include:
This diverse portfolio reflects CLSA's commitment to investing in companies that are poised to make a significant impact on patient care and the healthcare industry as a whole.
Mark Chance, Ph.D. - Scientific Diligence. Mark has extensive experience in the life sciences sector and plays a crucial role in evaluating scientific opportunities for investment.
Beno Michel, MD - Scientific Diligence. Beno brings a medical perspective to the firm, focusing on the clinical implications of potential investments.
Michael Ellis, JD - Venture Counsel. Michael provides legal guidance and support for the firm's investment activities, ensuring compliance and strategic alignment.
Arthur Elk, JD - Business Diligence. Arthur evaluates business models and market strategies for potential portfolio companies.
Robert Hurwitz - Business Diligence. Robert contributes to the assessment of business opportunities and market potential.
Jessica Scarborough, Ph.D., MD - Venture Consultant. Jessica offers insights into the scientific and medical aspects of potential investments, enhancing the firm's diligence process.
Abigail Longnaker - Investor Relations Intern. Abigail assists with communications and relationship management within the firm.
Rupleen Kaur - CLSA Intern. Rupleen supports various operational functions within the organization.
To pitch to Cleveland Life Science Advisors, founders should use the contact email info@clsafund.com. A well-structured pitch deck is essential, including details about the business model, market opportunity, and team qualifications. While specific response time expectations are not publicly stated, founders should anticipate a thorough review process given the firm's focus on impactful investments.
Warm introductions are beneficial, especially from mutual connections within the life sciences sector or academic institutions. Founders are encouraged to clearly articulate how their technology aligns with CLSA's focus on patient care and market potential.
As of 2023, Cleveland Life Science Advisors has been actively investing in innovative life sciences ventures, as evidenced by their notable portfolio companies. However, there have been no recent public announcements or updates regarding new investments or exits.
In 2022, CLSA announced the establishment of the Cleveland Life Sciences Accelerator Fund, which has a fund size of approximately $2.7 million. This fund is backed by around 24 individual investors and focuses on early-stage life sciences companies in the Greater Midwest.
CLSA continues to emphasize its commitment to fostering innovation in the life sciences sector, particularly through partnerships with academic institutions like Case Western Reserve University.
What are CLSA's investment criteria?
CLSA focuses on early-stage companies in the life sciences sector, particularly those with strong intellectual property and exceptional market opportunities. They target sectors such as biotech and healthcare.
How can I pitch to CLSA?
Founders can pitch to CLSA by visiting their website at clsafund.com and using the contact email info@clsafund.com. A well-prepared pitch deck that outlines the business model, market opportunity, and team is recommended.
What makes CLSA different from other investors?
CLSA emphasizes both financial returns and humanitarian impact, focusing on technologies that significantly improve patient care. Their strong ties to academic institutions provide additional resources and support for portfolio companies.
What is CLSA's geographic focus?
CLSA primarily invests in companies located in North America, with a specific emphasis on Cleveland and the Greater Midwest.
What is the typical check size for investments?
While specific check sizes are not publicly disclosed, CLSA operates with a fund size of approximately $2.7 million, indicating a focus on early-stage investments.
What kind of support do portfolio companies receive?
CLSA provides strategic guidance, access to a network of industry experts, and partnerships with academic institutions to help portfolio companies navigate early-stage challenges and achieve growth.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.